Our purpose is to push the boundaries of science to deliver life-changing medicines. As a global organisation, we work together to bring life-changing medicines to millions of patients.
Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1
Meet our cohesive community of ambitious, like-minded entrepreneurs.Home to 7,250 people working in over 130 innovative companies.Take a look at the roster of companies working on some of the world's biggest ideas.Travel options for commuters and visitors and information on our transport initiativesWe've got some of the best facilities in Europe to put brilliant companies leagues ahead.CSP events are a great way to meet people, make friends and identify potential business partners.Get in touch with our helpful team to find out all about who we are and how we work.
We do this by embedding human target validation earlier in research, taking an innovative approach to clinical trial design and integrating multiple data sources to share timely scientific insights across our focus areas. Pushing the boundaries of medicinal chemistry enables the delivery of new candidate drugs into our pipeline, and is the foundation of small molecule drug discovery across the company.Our Antibody Discovery and Protein Engineering Team applies cutting-edge technologies in the discovery of novel therapeutic biologics to change the lives of patients. If you are in the United States and would like additional information regarding AstraZeneca products, or you are a third party with an offer of services for AstraZeneca, you can contact the AstraZeneca Information Center by phone at 1-800-236-9933 (Monday-Friday, 8am-6pm ET, excluding holidays). With a number of PhD programmes with the University of Cambridge through to our ongoing commitment to STEM programmes in the local community, we are passionate about finding new ways to ensure we support, develop and inspire the next generation of Cambridge scientists.
For example, our drug discovery scientists are working with Microsoft to use a cloud-based simulation tool that brings alive the millions of potential changes that make cancer cells multiply uncontrollably, to better understand the disease.Similarly, scientists from AstraZeneca and Cancer Research UK are working together to discover and develop novel biologics to treat cancer.
Press enter to search
We do this by combining our expertise in companion diagnostics with laboratory science in molecular diagnostics, tissue diagnostics, imaging and protein biomarkers and working with external partners to harness breakthrough technologies, throughout the life-cycle of our medicines.Our Early Clinical Development team designs and delivers early phase development strategies and exploratory studies that build the credentials of novel targets. Once completed, more than 2,000 AstraZeneca and MedImmune R&D science jobs will be on the CBC site, delivering more knowledge sharing, skills and expertise – and ultimately for pushing the boundaries of science. We have an exceptional track record of delivery, having discovered and engineered almost 100 protein therapeutics that have entered the clinic.Our translational expertise enables us to accelerate the development of new druggable targets in human disease and select the right patients in early clinical trials.
The team works collaboratively across all therapy areas, using a range of innovative in-house platform technologies such as phage and ribosome display, Fc engineering and novel peptide discovery methodologies. Life Sciences Our country sites can be located in the AZ Network. Our global locations.